Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc.ARQT · Entity 4236 | Director | June 15, 2026 | June 18, 2026 |
| Stevanato Group S.p.A.STVN · Entity 3826 | Director | June 12, 2026 | June 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arcutis Biotherapeutics, Inc.
Report date June 15, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 27,567 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Sale · Disposed 4,946 · Balance 27,567 F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025, by the Reporting Person, with a plan end date of February 19, 2027. F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.045 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025, by the Reporting Person, with a plan end date of February 19, 2027.
F2: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.045 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Stevanato Group S.p.A.
Report date June 12, 2026 · Filed June 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 6,975 |
Reported balance
After 2026-06-12 transaction · row 1
1 source rowRow 1 · 2026-06-12 · Grant · Acquired 4,975 · Balance 6,975 F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director |
Filing footnotes · ownership attribution and instrument terms
F1: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2026 Filed Jun 18, 2026 00:47 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 4,946 | $24.38 | $120,586.94 |
DisclosureSEC source: 0001628280-26-044083 · wk-form4_1781743626.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,567 F1 · kind: The transaction reported in this Form 4 was effected pursuant to a 10b5-1 trading plan adopted on December 4, 2025, by the Reporting Person, with a plan end date of February 19, 2027. F2 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $24.045 to $24.62, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 12, 2026 Filed Jun 26, 2026 10:14 UTC | Stevanato Group S.p.A. STVN · Entity 3826 | GrantOrdinary Shares | 4,975 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-283812 · ownership.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,975 F1 · shares: Represents ordinary shares granted as equity compensation in connection with the Reporting Person's service as director Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 16,667 | $0.00 Strike: $21.23 | $0.00 |
DisclosureSEC source: 0001628280-26-042045 · wk-form4_1781054483.xml · derivative · entry 2 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,667 Underlying: Common Stock · 16,667 shares Expires 2036-06-05 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 05, 2026 Filed Jun 10, 2026 01:21 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 5,778 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-042045 · wk-form4_1781054483.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,513 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2026 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 5, 2026, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 26, 2025, maintained by the Company. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 7,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001867788-25-000005 · wk-form4_1764113246.xml · derivative · entry 5 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 7,220 shares Expires 2033-05-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionStock Option (right to buy) · Derivative | 18,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001867788-25-000005 · wk-form4_1764113246.xml · derivative · entry 4 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,000 Underlying: Common Stock · 18,052 shares Expires 2034-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | SaleCommon Stock | 25,272 | $30.78 | $777,955.56 |
DisclosureSEC source: 0001867788-25-000005 · wk-form4_1764113246.xml · nonDerivative · entry 3 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,735 F3 · kind: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · price: The price reported in Column 4 is a weighted average sale price. The shares were sold in multiple transactions at prices ranging from $30.56 to $30.91, inclusive. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 7,220 | $7.51 | $54,222.20 |
DisclosureSEC source: 0001867788-25-000005 · wk-form4_1764113246.xml · nonDerivative · entry 2 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023, subject to the non-employee director's continuous service. Read SEC document |
| November 24, 2025 Filed Nov 25, 2025 23:27 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | Exercise / conversionCommon Stock | 18,052 | $8.63 | $155,788.76 |
DisclosureSEC source: 0001867788-25-000005 · wk-form4_1764113246.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 20,568 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0002065881-25-000029 · wk-form4_1750119481.xml · derivative · entry 2 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,568 Underlying: Common Stock · 20,568 shares Expires 2035-06-12 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Read SEC document |
| June 12, 2025 Filed Jun 17, 2025 00:18 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 7,609 | $0.00 | $0.00 |
DisclosureSEC source: 0002065881-25-000029 · wk-form4_1750119481.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,735 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 21, 2024, maintained by the Company. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 27,052 | $0.00 Strike: $8.63 | $0.00 |
DisclosureSEC source: 0001787306-24-000101 · wk-form4_1718743896.xml · derivative · entry 2 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,052 Underlying: Common Stock · 27,052 shares Expires 2034-06-14 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to the non-employee director's continuous service. Read SEC document |
| June 14, 2024 Filed Jun 18, 2024 20:51 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 10,139 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-24-000101 · wk-form4_1718743896.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,126 F1 · shares: Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2024 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. The RSUs vest in full on the one-year anniversary of the date of grant, subject to the non-employee director's continuous service. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:22 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (right to buy) · Derivative | 12,220 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001787306-23-000064 · wk-form4_1685748130.xml · derivative · entry 2 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,220 Underlying: Common Stock · 12,220 shares Expires 2033-05-31 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of May 31, 2023. Read SEC document |
| May 31, 2023 Filed Jun 2, 2023 23:22 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,375 | $0.00 | $0.00 |
DisclosureSEC source: 0001787306-23-000064 · wk-form4_1685748130.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,987 F1 · balance_after: Includes 4,375 Restricted Stock Units (?RSUs?). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 11,796 | $0.00 Strike: $20.29 | $0.00 |
DisclosureSEC source: 0001567619-22-012315 · doc1.xml · derivative · entry 2 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 Underlying: Common Stock · 11,796 shares Expires 2032-06-01 F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% on the first anniversary of June 1, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 20:54 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantCommon Stock | 4,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-012315 · doc1.xml · nonDerivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,612 F1 · balance_after: Includes 4,612 Restricted Stock Units ("RSUs"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| June 09, 2021 Filed Jun 16, 2021 18:07 UTC | Arcutis Biotherapeutics, Inc. ARQT · Entity 4236 | GrantStock Option (Right to Buy) · Derivative | 25,723 | $0.00 Strike: $27.77 | $0.00 |
DisclosureSEC source: 0001567619-21-012178 · doc1.xml · derivative · entry 1 LIN SUE-JEAN · CIK 0001867788 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,723 Underlying: Common Stock · 25,723 shares Expires 2031-06-09 F1 · derivative.exercise_date: The option vests as to 1/3rd of the total shares on each of June 9, 2022, June 9, 2023 and June 9, 2024, subject to Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.